Provided by Tiger Trade Technology Pte. Ltd.

AbbVie

259.93
-1.6600-0.63%
Post-market: 260.460.5300+0.20%19:54 EDT
Volume:3.89M
Turnover:1.01B
Market Cap:459.40B
PE:73.43
High:262.32
Open:260.51
Low:259.00
Close:261.59
52wk High:269.39
52wk Low:190.75
Shares:1.77B
Float Shares:1.76B
Volume Ratio:1.03
T/O Rate:0.22%
Dividend:6.83
Dividend Rate:2.63%
EPS(TTM):3.54
EPS(LYR):2.36
ROE:6225.00%
ROA:10.51%
PB:-77.40
PE(LYR):110.14

Loading ...

AbbVie (ABBV) Stock May Be 41% Undervalued On FDA Approval

Simply Wall St.
·
6 hours ago

AbbVie Says Phase 3 Trials Show Rinvoq Vitiligo Repigmentation Gains Extend to Week 76

Reuters
·
Yesterday

Abbvie - Phase 3 Studies Show Continued Repigmentation with Rinvoq Through Week 76

THOMSON REUTERS
·
Yesterday

Abbvie - Rinvoq Plus NB-Uvb Shows Higher Repigmentation than Rinvoq Alone

THOMSON REUTERS
·
Yesterday

AbbVie to Host Third-Quarter 2026 Earnings Call Webcast

Reuters
·
Yesterday

InflaRx Appoints Gabriela Alperovich as SVP, Global Head of Clinical Development

Reuters
·
Yesterday

AbbVie Wraps Key Early Trial on ABBV-722 Drug Interaction, Supporting Pipeline Confidence

TIPRANKS
·
Yesterday

AbbVie’s Bretisilocin Study Completion Signals Quiet Progress in Early-Stage Pipeline

TIPRANKS
·
Yesterday

Major Drugmakers Turn to China for Licensing Deals

Reuters
·
Sep 30

AbbVie reports ‘positive’ results from Phase 2 APEX Part B study of zumilokibart

TIPRANKS
·
Sep 30

AbbVie Starts Phase 2 Obesity Trial of Gubra-Discovered Amylin Analog ABBV-295

Reuters
·
Sep 30

Abbvie: in Phase 1 Abbv-295 Study, All Dosing Regimens Resulted in Ls Mean Weight Loss up to About 10% over 3-Month Treatment Period

THOMSON REUTERS
·
Sep 30

Abbvie: 82.2% of All Abbv-295 Treated Participants Reported Mild Adverse Events as Highest Reported Ae Severity

THOMSON REUTERS
·
Sep 30

AbbVie Says Phase 1 ABBV-295 Study Shows Mean Weight Loss up to About 10% over 3-Month Period

Reuters
·
Sep 30

AbbVie Says Mid-Stage Study of Atopic Dermatitis Treatment Meets Primary Goal

MT Newswires Live
·
Sep 30

Abbvie Highlights Positive Results from the Phase 2 Apex Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at Eadv 2026

THOMSON REUTERS
·
Sep 30

AbbVie Presents Phase 2 APEX Part B Data for Zumilokibart in Moderate-to-Severe Atopic Dermatitis at EADV 2026

Reuters
·
Sep 30

AbbVie Inc. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Sep 30

AbbVie Shows Pipeline-Driven Upside Beyond Core Immunology Franchise, BofA Says

MT Newswires Live
·
Sep 29

Ginkgo Datapoints, Apheris, AbbVie, and Others Form Antibody Developability Consortium

MT Newswires Live
·
Sep 29